Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-07-22

FDA Approved: DALVANCE — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved Allergan's supplemental application for DALVANCE (dalbavancin), resulting in changes to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dalvance (dalbavancin)

Snippet

SUPPL AP for DALVANCE (DALBAVANCIN)